
Andrew’s research focus involves designing and testing stabilised glycoproteins for medical applications.
Dr Andrew Young is a Senior Research Fellow working on the stabilisation of glycoproteins for the development of vaccines against common viral diseases. He completed his PhD at the University of Queensland in 2019 and has since helped develop vaccines for Respiratory Syncytial Virus (RSV), human Metapneumovirus (HMPV) and Parainfluenza virus type 3 (PIV3) that have advanced to clinical trials. His PhD focussed primarily on Ebola and other filoviruses, where he developed stabilised subunit vaccine candidates and proof-of-concept diagnostics.
Industry
Dr Young consults for Sanofi on vaccine development.
Key Publications
Young A, Kolekar S, Mendoza CA, Jaberolansar N, Modhiran N, Webb T, McCuaig R, Kommajosyula V, Tardiota N, Dy Q, Amarilla AA, Dalrymple RL, Gillard M, Dutton JL, Magdalena J, Vandendriessche F, Smal J, Young PR, Watterson D, Hanon EJ, Chappell KJ. A second-generation molecular clamp stabilised bivalent candidate vaccine for protection against diseases caused by respiratory syncytial virus and human metapneumovirus. PLoS Pathog. 2025 Jul 17;21(7):e1013312. doi: 10.1371/journal.ppat.1013312. PMID: 40674411; PMCID: PMC12270161.
Watterson, D., Wijesundara, D.K., Naphak Modhiran, Mordant, F.L., Li, Z., Michael Selorm Avumegah, Christopher, Lackenby, J., Guilfoyle, K., Geert van Amerongen, Stittelaar, K.J., Stacey, Bibby, S., Daleris, M., Hoger, K., Gillard, M., Radunz, E., Jones, M.L., Hughes, K., Hughes, B., ... (2021). Preclinical development of a molecular clamp‐stabilised subunit vaccine for severe acute respiratory syndrome coronavirus 2. Clinical & translational immunology, 10(4). doi:https://doi.org/10.1002/cti2.1269.
Isaacs, A., Cheung, S.T.M., Thakur, N., Jaberolansar, N., Young, A., Modhiran, N., Bailey, D., Graham, S.P., Young, P.R., Chappell, K.J. and Watterson, D. (2021). Combinatorial F-G Immunogens as Nipah and Respiratory Syncytial Virus Vaccine Candidates. Viruses, [online] 13(10), p.1942. doi:https://doi.org/10.3390/v13101942.
| Featured projects | Duration |
|---|---|
| ViceBio | 2019–2024 |